Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab in Moderate to Severe Atopic Dermatitis (M16-813)
jRCT2080224583Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Risankizumab with Placebo (2 arms). Primary endpoint: EASI 75 at Week 16. Started Mar 2019; status: completed.
02
Drugs
risankizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2080224583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224583.